Pharmaceutical company Mylan NV (Nasdaq:MYL)(TASE:MYL) reported on Tuesday the availability of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg in the US market.
The company added that the US Food and Drug Administration (FDA) has approved Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.
According to IMS Health, Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg had US sales of about USD51.1m for the 12 months ending 30 September 2015.
Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg is the generic version of Jazz Pharmaceutical's FazaClo.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia